Elorac acquires world-wide rights to Cidoxepin

Links shared publicly online about this topic.

791
total visits

Elorac acquires world-wide rights to Cidoxepin

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, is pleased to announce that it has acquired world-wide rights to the active agent Cidoxepin from Gideon Pharmaceuticals. Cidoxepin is the cis-isomer of the widely prescribed tricyclic compound doxepin.

View full resource at news-medical.net

Tags: Dermatology, Disease and Condition, Pharma